TEAMLEUKEMIA - TREATMENT EVOLUTION ON ACUTE MYELOID LEUKEMIA

1. 1.Candoni A et al. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.. Hematol Rep. 2024 Apr 18;16(2):244-254. doi: 10.3390/hematolrep16020024. PMID: 38651453; PMCID: PMC11036224.. 2024
   Articolo scientificoHematol Rep. 2024 Apr 18;16(2):244-254. doi: 10.3390/hematolrep16020024. PMID: 38651453; PMCID: PMC11036224.Leggi il PDF gratuito
2. 2.Venditti A et al. Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.. Blood Adv. 2025 May 13;9(9):2207-2220. doi: 10.1182/bloodadvances.2024013744. PMID: 39913928; PMCID: PMC12083920.. 2025
   Articolo scientificoBlood Adv. 2025 May 13;9(9):2207-2220. doi: 10.1182/bloodadvances.2024013744. PMID: 39913928; PMCID: PMC12083920.Cerca su Google Scholar
3. 3.Cairoli R et al. Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.. Cancer. 2025 Sep 1;131(17):e70055. doi: 10.1002/cncr.70055. PMID: 40839405; PMCID: PMC12369923.. 2025
   Articolo scientificoCancer. 2025 Sep 1;131(17):e70055. doi: 10.1002/cncr.70055. PMID: 40839405; PMCID: PMC12369923.Cerca su Google Scholar

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).